Department of Pharmacy, Charleston Area Medical Center, Charleston, WV, USA.
J Clin Pharm Ther. 2011 Jun;36(3):433-6. doi: 10.1111/j.1365-2710.2010.01214.x. Epub 2010 Nov 10.
Wangiella dermatitidis is a darkly pigmented fungus that has been isolated from the soil, dead plant material and areas of high humidity. Infection from the pathogen has not been extensively documented and few published cases report survival. Of the antifungal agents used in previous reports, none has been proven to improve outcomes. Voriconazole is known to have in vitro activity against the organism, but clinical experience for the treatment of W. dermatitidis infection is limited. The objective of this case report is to describe the use of voriconazole for the treatment of W. dermatitidis infection.
An 86-year-old American woman with a past medical history significant only for mild dementia is successfully treated for pulmonary W. dermatitidis infection using oral voriconazole monotherapy with minimal adverse effects.
Voriconazole appears to be effective as monotherapy for the treatment of pulmonary W. dermatitidis infections. A minimum of 3-4 months of antifungal treatment should be given. Adverse effects with prolonged voriconazole use do not appear to be a barrier to treatment.
Wangiella dermatitidis 是一种深色色素真菌，已从土壤、死亡植物材料和高湿度区域中分离出来。该病原体的感染尚未广泛记录，少数已发表的病例报告显示患者存活。在以前的报告中使用的抗真菌药物中，没有一种被证明能改善预后。已知伏立康唑对该生物体具有体外活性，但治疗 W. dermatitidis 感染的临床经验有限。本病例报告的目的是描述使用伏立康唑治疗 W. dermatitidis 感染。
一名 86 岁的美国妇女，既往病史仅为轻度痴呆，她成功地接受了口服伏立康唑单药治疗，用于治疗肺部 W. dermatitidis 感染，且副作用极小。
伏立康唑似乎是治疗肺部 W. dermatitidis 感染的有效单药治疗方法。应给予至少 3-4 个月的抗真菌治疗。延长伏立康唑使用的不良反应似乎不会成为治疗的障碍。
